# US 2023/0055908 A1 · Mesylate salt of para-topolin, compositions containing said salt and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0055908 A1
- Document ID: US20230055908A1
- Status: Published application
- Kind: A1
- Application number: 17/613,221
- Filed: 2020-08-22
- Published: 2023-02-23
- Earliest claimed: 2020-05-17
- Assignees: Ustav Experimentalni Botaniky Av Cr, V. V. I.
- Applicants: Ustav Experimentalni Botaniky Av Cr, V. V. I.
- Inventors: Lucie PLIHALOVA; Marek ZATLOUKAL; Karel DOLEZAL; Miroslav STRNAD; Jan WALLA; Jiri VOLLER
- Web page: https://patentgrep.com/patent/US20230055908A1

## CPC

- C07D 473/34: attached in position 6, e.g. adenine
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

A para-topolin mesylate salt and its crystalline form is disclosed. Cosmetic and therapeutic applications, and compositions containing this compound, are also disclosed. Mesylate salt of para-topolin has a wide range of biological activities, including antioxidative, anti-inflammatory, anti-senescent and anti-aging while showing low toxicity and excellent solubility.

## Claims

### Claim 1

6-(4-hydroxybenzylamino) purinium mesylate.

### Claim 2

Crystalline form of 6-(4-hydroxybenzylamino) purinium mesylate characterized by an CuKα X-ray powder diffration pattern having characteristic peaks at 9.0; 9.2; 17.0; 17.9; 18.1; 22.3; 22.4; 24.1; 26.4 ± 0.2° 2-theta.

### Claim 3 (depends on 2)

Crystalline form according to claim 2, having further characteristic peaks in the X-ray powder diffration pattern measured by CuKα radiation: 13.6; 15.6; 16.3; 16.7; 19.8; 25.7; 27.2 ± 0.2° 2-theta.

### Claim 4 (depends on 1)

A method of treatment, comprising the step of administering a medicament comprising 6-(4-hydroxybenzylamino) purinium mesylate according to claim 1 to a subject in need thereof .

### Claim 5 (depends on 1)

A method of treatment or improvement of a condition, comprising the step of administering 6-(4-hydroxybenzylamino) purinium mesylate according to claim 1 to a subject in need thereof, wherein the condition is selected from the group consisting of skin disease, skin condition, neurodegenerative disease, imunostimulation and inflammation.

### Claim 6 (depends on 1)

A method of prevention and/or treatment of a disease or condition, comprising the step of administering 6-(4-hydroxybenzylamino) purinium mesylate according to claim 1 to a subject in need thereof, wherein the disease or condition is selected from the group consisting of skin cancer, psoriasis, fibrotic disorders, scleroderma, graft versus host disease (GVHD), hypertrophic scars, nephrogenic systemic fibrosis, allergic eczema, toxic eczema, atopic dermatitis, lichen planus, hyperpigmentation and herpes simplex lesions, ichthyosis, papilloma, Bowen’s disease, seborrheic keratoses, actinic keratoses, basal and squamous cell carcinoma, arthritis, transplant rejection, pain, erythrema and redness.

### Claim 7 (depends on 1)

A method of prevention and/or treatment, comprising the step of administering 6-(4-hydroxybenzylamino) purinium mesylate according to claim 1, as a cosmetic active ingredient, to a subject in need thereof.

### Claim 8 (depends on 7)

The method of prevention and/or treatment according to claim 7, wherein the treatment is selected from the group consisting of rejuvenating cells and tissues; improving the overall appearance and condition of skin; improvement in acne and/or erythema; reduction of redness; reducing number and/or depth of wrinkles and/or lines; improvement of a condition selected from the group consisting of sagging skin, discoloration, appearance of age spots, leathery and/or yellowed areas of skin; and improving the cosmetic appearance of skin.

### Claim 9 (depends on 1)

A method of prevention and/or treatment, comprising the step of administering 6-(4-hydroxybenzylamino) purinium mesylate according to claim 1 to a subject in need thereof, the method comprising administration in a context selected from the group consisting of in vitro for rejuvenating cells and tissues, stimulating cell proliferation, morphogenesis and/or differentiation, inhibiting cell aging and inhibiting tissue aging.

### Claim 10 (depends on 1)

A cosmetic and/or pharmaceutical composition, characterized in that it comprises 6-(4-hydroxybenzylamino) purinium mesylate according to claim 1 and at least one cosmetically and/or pharmaceutically acceptable excipient.

### Claim 11 (depends on 1)

A method of treatment or improvement of skin disease, skin condition, or neurodegenerative disease, said method comprising administering 6-(4-hydroxybenzylamino) purinium mesylate according to claim 1 to a subject in need thereof .

### Claim 12 (depends on 1)

A method for suppression of imunostimulation or inflammation, said method comprising the step of administering 6-(4-hydroxybenzylamino) purinium mesylate according to claim 1 to a subject in need thereof .

### Claim 13 (depends on 1)

A method of prevention and/or treatment of a disease and/or condition, wherein the disease and/or condition is selected from the group consisting of skin cancer, psoriasis, fibrotic disorders, scleroderma, graft versus host disease (GVHD), hypertrophic scars, nephrogenic systemic fibrosis, allergic eczema, toxic eczema, atopic dermatitis, lichen planus, hyperpigmentation and herpes simplex lesions, ichthyosis, papilloma, Bowen’s disease, seborrheic keratoses, actinic keratoses, basal and squamous cell carcinoma, arthritis, transplant rejection, pain, erythrema and redness, said method comprising the step of administering 6-(4-hydroxybenzylamino) purinium mesylate according to claim 1 to a subject in need thereof .

### Claim 14 (depends on 1)

A method for achieving a therapeutic outcome, the therapeutic outcome selected from the group consisting of rejuvenating the cells and tissues; improving the overall appearance and condition of the skin; improvement in acne and/or erythema; reduction of redness; reducing number and/or depth of wrinkles and/or lines; improvement of a condition selected from the group consisting of sagging skin, discoloration, appearance of age spots, leathery and/or yellowed areas of the skin; and improving cosmetic appearance of skin, said method comprising administering 6-(4-hydroxybenzylamino) purinium mesylate according to claim 1 to a subject in need thereof .

### Claim 15 (depends on 1)

A method of prevention and/or treatment, the method comprising administration in a context selected from the group consisting of in vitro rejuvenating cells and tissues, stimulating cell proliferation, morphogenesis and/or differentiation, inhibiting cell aging and inhibiting tissue aging, said method comprising applying 6-(4-hydroxybenzylamino) purinium mesylate according to claim 1 to cells and/or tissues.
